|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/5377 | |
| A61K 45/06 | |||
| A61P 35/00 | |||
| A61K 31/44 | |||
| A61K 31/506 |
| (11) | Number of the document | 3215158 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15795318.3 |
| Date of filing the European patent application | 2015-11-06 | |
| (97) | Date of publication of the European application | 2017-09-13 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/059512 |
| Date | 2015-11-06 |
| (87) | Number | WO 2016/073877 |
| Date | 2016-05-12 |
| (30) | Number | Date | Country code |
| 201462077127 P | 2014-11-07 | US |
| (72) |
BEEHARRY, Neil, US
GAYLE, Sophia, US
LANDRETTE, Sean, US
BECKETT, Paul, US
CONRAD, Chris, US
XU, Tian, US
ROTHBERG, Jonathan, M., US
LICHENSTEIN, Henri, US
|
| (73) |
AI Therapeutics, Inc.,
530 Old Whitfield Street, Guilford, CT 06437,
US
|
| (54) | APILIMOD FOR USE IN THE TREATMENT OF RENAL CANCER |
| APILIMOD FOR USE IN THE TREATMENT OF RENAL CANCER |